Affordable Access

deepdyve-link
Publisher Website

The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.

Authors
  • Murakami, Miho1
  • Nishimoto, Norihiro
  • 1 Laboratory of Immune Regulation, Wakayama Medical University, Wakayama City, Wakayama, Japan. , (Japan)
Type
Published Article
Journal
Current opinion in rheumatology
Publication Date
May 01, 2011
Volume
23
Issue
3
Pages
273–277
Identifiers
DOI: 10.1097/BOR.0b013e3283456797
PMID: 21427577
Source
Medline
License
Unknown

Abstract

Blocking IL-6 with tocilizumab can be a therapeutic option for patients with various IMIDs in which overproduction of IL-6 plays a pathological role. Future clinical studies investigating the safety and efficacy will elucidate the clinical benefits of IL-6 blockade therapy for such diseases.

Report this publication

Statistics

Seen <100 times